Fig. 6.
Deficiency of Bax enhances Mpl ligand–mediated hematopoietic recovery after the myelosuppressive regimen.
PEG-rmMGDF was immediately administered toBax−/− mice (Bax KO, n = 17) and wild-type (WT, B6/129 mice, usually littermates, n = 17) after lethal myelosuppression. Carrier-treated Bax−/− mice (n = 12) and wild-type mice (n = 10). Each point represents mean ± SEM.